On January 9, 2025, the 2025 Global NGP Compliance Development Symposium, successfully concluded in Shenzhen. The symposium aimed to promote global compliance development and advocate for companies to actively embrace the new era of compliance. More than 10 renowned compliance industry experts and representatives from China and around the world delivered keynote speeches in a combination of online and offline formats, attracting nearly 200 participants from various sectors, including international tobacco companies, leading e-cigarette companies in China, top supply chain companies, and research scholars. The symposium was organized by the globally leading NGP industry media - 2Firsts.
Dr. Andrea Patton, a behavioral epidemiologist and head of research at the Centre for Substance Use Research (CSUR), participated in the symposium and delivered an online presentation on the topic "Opportunities and Challenges for Businesses Applying for PMTA in 2025."
Dr. Andrea Patton analyzed the opportunities and challenges that companies will face when applying for PMTA in 2025 during her speech. She pointed out that PMTA applications must meet the standard of "appropriate for protecting public health," which means proving that the benefits of the product to adult smokers outweigh the risks to adolescents and non-smoking adults, requiring the quantification of the product's benefits and risks.
Additionally, the PMTA application involves multidisciplinary research and is costly. Dr. Andrea Patton recommends collaborating with experts and utilizing data on the popularity of tobacco products from the CSUR to reduce costs. She emphasizes that compliance helps businesses provide safer alternatives for the 28 million smoking adults in the United States, reduce smoking rates, and meet public health needs.
At the 2025 Global NGP Compliance Development Symposium, Dr. Andrea Patton's professional speech won widespread praise and enthusiastic response from attendees. After the speech, many participants expressed that the information provided valuable industry insights and compliance guidance, helping them to gain a deeper understanding of key standards for PMTA applications, methods for quantifying product benefits and risks, and the complexity of multidisciplinary research. At the same time, attendees also expressed sincere gratitude to the two organizers. They believed that the organizers had built a high-quality compliance communication platform, greatly facilitating communication and interaction among various industry stakeholders and effectively promoting the industry's steady development on the compliance path.
As a leading media and consultancy in the global Next Generation Products (NGP) field, 2Firsts actively maintains close contact with various testing agencies and regulatory bodies, building a solid bridge for industry resource sharing and information exchange. In the future, 2Firsts will continue to integrate resources, consolidate wisdom, and work together with industry partners to promote the high-quality development of the global NGP industry, contributing lasting strength to industry innovation breakthroughs and compliant progress.
Regarding CSUR
The Centre for Substance Use Research (CSUR) is an independent research institute located in Glasgow, Scotland. They specialize in providing behavioral science research and consulting services to the tobacco and e-cigarette industries. CSUR assists companies in conducting necessary behavioral research to help with regulatory approvals such as PMTA, MRTP, and EU TPD, ensuring compliant product launches. Their team consists of experts in behavioral science, marketing, and other fields, and they have close collaborations with several prominent tobacco companies.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
